Hsp90 ensures the transition from the early Ca2+-dependent to the late phosphorylation-dependent activation of the endothelial nitric-oxide synthase in vascular endothelial growth factor-exposed endothelial cells

Author(s): Brouet A, Sonveaux P, Dessy C, Balligand JL, Feron O

Abstract

Vascular endothelial growth factor (VEGF) exerts its angiogenic effects partly through the activation of endothelial nitric-oxide synthase (eNOS). Association with heat shock protein 90 (hsp90) and phosphorylation by Akt were recently shown to separately activate eNOS upon VEGF stimulation in endothelial cells. Here, we examined the interplay between these different mechanisms in VEGF-exposed endothelial cells. We documented that hsp90 binding to eNOS is, in fact, the crucial event triggering the transition from the Ca(2+)-dependent activation of eNOS to the phosphorylation-mediated potentiation of its activity by VEGF. Accordingly, we showed that early VEGF stimulation first leads to the Ca(2+)/calmodulin disruption of the caveolin-eNOS complex and promotes the association between eNOS and hsp90. eNOS-bound hsp90 can then recruit VEGF-activated (phosphorylated) Akt to the complex, which in turn can phosphorylate eNOS. Further experiments in transfected COS cells expressing either wild-type or S1177A mutant eNOS led us to identify the serine 1177 as the critical residue for the hsp90-dependent Akt-mediated activation of eNOS. Finally, we documented that although the VEGF-induced phosphorylation of eNOS leads to a sustained production of NO independently of a maintained increase in [Ca(2+)](i), this late stage of eNOS activation is strictly conditional on the initial VEGF-induced Ca(2+)-dependent stimulation of the enzyme. These data establish the critical temporal sequence of events leading to the sustained activation of eNOS by VEGF and suggest new ways of regulating the production of NO in response to this cytokine through the ubiquitous chaperone protein, hsp90.

Similar Articles

Costs and duration of care for lower extremity ulcers in patients with diabetes

Author(s): Holzer SE, Camerota A, Martens L, Cuerdon T, Crystal-Peters J, et al.

The L-arginine-nitric oxide pathway

Author(s): Moncada S, Higgs A

Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy

Author(s): Nakagawa T, Sato W, Glushakova O, Heinig M, Clarke T, et al.

eNOS gene polymorphism association with retinopathy in type 1 diabetes

Author(s): Bazzaz JT, Amoli MM, Pravica V, Chandrasecaran R, Boulton AJ, et al.

eNOS4 polymorphism of the endothelial nitric oxide synthase predicts risk for severe diabetic retinopathy

Author(s): Taverna MJ, Sola A, Guyot-Argenton C, Pacher N, Bruzzo F, et al.

Endothelial nitric oxide synthase VNTR (intron 4 a/b) polymorphism association with type 2 diabetes and its chronic complications

Author(s): Mehrab-Mohseni M, Tabatabaei-Malazy O, Hasani-Ranjbar S, Amiri P, Kouroshnia A, et al.

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

Author(s): Wild S, Roglic G, Green A, Sicree R, King H

Ethnic India: a genomic view, with special reference to peopling and structure

Author(s): Basu A, Mukherjee N, Roy S, Sengupta S, Banerjee S, et al.

Endothelial nitric oxide synthase gene haplotypes and diabetic nephropathy among Asian Indians

Author(s): Ahluwalia TS, Ahuja M, Rai TS, Kohli HS, Sud K, et al.

Endothelial nitric oxide synthase gene polymorphism and acute myocardial infarction

Author(s): Hibi K, Ishigami T, Tamura K, Mizushima S, Nyui N, et al.

Endothelial nitric oxide synthase gene is positively associated with essential hypertension

Author(s): Miyamoto Y, Saito Y, Kajiyama N, Yoshimura M, Shimasaki Y, et al.

Association of the missense Glu298Asp variant of the endothelial nitric oxide synthase gene with severe preeclampsia

Author(s): Yoshimura T, Yoshimura M, Tabata A, Shimasaki Y, Nakayama M, et al.